Therapeutic Areas

Ockham Oncology has global expertise in oncology trials across a broad range of indications. The graphs below are an overview of the number of trials completed organized by Solid Tumor or Hematological indications or by phase. For more details, explore the tables below. Filter by indication, phase, or region, and then link to the study for more information.

  • View by Type
  • Solid Tumor
  • Hematological
  • View by Indication
  • AML
  • Bladder
  • Breast
  • Chemo Induced Neutropaenia
  • Cholangiocarcinoma
  • CLL
  • Colorectal
  • Endometrial
  • GBM
  • HCC
  • Head & Neck
  • Intestine
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myelofibrosis
  • Ovarian
  • Pancreatic
  • PHI-HaemOnc
  • PHI-ST
  • Prostate
  • Renal
  • Tumour defined by Biomarker
  • View by Phase
  • Phase BE
  • Phase I
  • Phase I/II
  • Phase I/IIa
  • Phase II
  • Phase II/III
  • Phase IIb
  • Phase III
  • Phase IIIb
  • View by Region
  • Global
  • North America
  • Europe
# Indication Type Phase Region
1 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 30
ST Phase I EU
2 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 10
ST Phase I EU
3 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 37
ST Phase I EU
4 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 36
ST Phase I EU
5 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 40
ST Phase I EU
6 Head & Neck
Sites: 2 Countries: United Kingdom
Patients: 30
ST Phase I/II EU
7 CLL
Sites: 22 Countries: France, Germany, Poland, Sweden, United Kingdom
Patients: 80
H-O Phase II EU
8 Lymphoma
Sites: 30 Countries: Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Sweden, United Kingdom
Patients: 35
H-O Phase II EU
9 PHI-HaemOnc
Sites: 8 Countries: Belgium, Germany, Netherlands, United Kingdom
Patients: 70
H-O Phase I/II EU
10 Lung
Sites: 10 Countries: France, Germany, Italy, Netherlands, United Kingdom
Patients: 45
ST Phase II EU
11 Prostate
Sites: 46 Countries: Belgium, France, Germany, Italy, Netherlands, Poland, Sweden, United Kingdom
Patients: 185
ST Phase III EU
12 Prostate
Sites: 1 Countries: United Kingdom
Patients: 60
ST Phase I EU
13 PHI-ST
Sites: 1 Countries: United Kingdom
Patients: 12
ST Phase I EU
14 CLL
Sites: 4 Countries: United Kingdom
Patients: 10
H-O Phase I EU
15 Head & Neck
Sites: 3 Countries: United Kingdom
Patients: 40
ST Phase II EU
16 Pancreatic
Sites: 3 Countries: Singapore, United Kingdom
Patients: 15
ST Phase I GL
17 Multiple Myeloma
Sites: 32 Countries: United Kingdom
Patients: 240
H-O Phase IIIb EU
18 PHI-ST
Sites: 1 Countries: United Kingdom
Patients: 40
ST Phase I EU
19 Lung
Sites: 1 Countries: Germany
Patients: 24
ST Phase I EU
20 Prostate
Sites: 1 Countries: United Kingdom
Patients: 35
ST Phase II EU
21 Chemo Induced Neutropaenia
Sites: 8 Countries: Poland & Hungary
Patients: 62
ST Phase I/II EU
22 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 12
ST Phase I EU
23 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 12
ST Phase I EU
24 PHI-ST
Sites: 4 Countries: United Kingdom
Patients: 24
ST Phase I EU
25 PHI-ST
Sites: 2 Countries: United States
Patients: 20
ST Phase I NA
26 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 40
ST Phase I EU
27 Prostate
Sites: 2 Countries: United Kingdom
Patients: 40
ST Phase I EU
28 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 24
ST Phase I EU
29 Prostate
Sites: 1 Countries: United Kingdom
Patients: 48
ST Phase I EU
30 CLL
Sites: 4 Countries: Belgium, France, Spain
Patients: 30
H-O Phase I EU
31 CLL
Sites: 14 Countries: Denmark, France, Hungary, United Kingdom, United States
Patients: 21
H-O Phase I GL
32 Prostate
Sites: 1 Countries: United Kingdom
Patients: 15
ST Phase II EU
33 PHI-ST
Sites: 3 Countries: United Kingdom
Patients: 30
ST Phase I EU
34 Myelofibrosis
Sites: 5 Countries: United Kingdom
Patients: 40
H-O Phase I EU
35 PHI-ST
Sites: 4 Countries: Taiwan, United States
Patients: 40
ST Phase I GL
36 PHI-ST
Sites: 1 Countries: United States
Patients: 36
ST Phase I NA
37 PHI-ST
Sites: 1 Countries: United States
Patients: 36
ST Phase I NA
38 Prostate
Sites: 72 Countries: Austria, Belgium, France, Germany, Hungary, Ireland, Italy, Netherlands, Poland, Spain, United Kingdom
Patients: 557
ST Phase III EU
39 Prostate
Sites: 15 Countries: Belgium, France, Netherlands, Poland
Patients: 60
ST Phase III EU
40 Colorectal
Sites: 1 Countries: United Kingdom
Patients: 15
ST Phase I EU
41 Pancreatic
Sites: 2 Countries: United Kingdom
Patients: 6
ST Phase IIb EU
42 PHI-ST
Sites: 3 Countries: United States
Patients: 30
ST Phase I NA
43 PHI-ST
Sites: 2 Countries: United States
Patients: 20
ST Phase I NA
44 PHI-ST
Sites: 2 Countries: United States
Patients: 20
ST Phase I NA
45 Lung
Sites: 20 Countries: Czech Republic, Germany, Hungary, United Kingdom
Patients: 100
ST Phase I/II EU
46 Breast
Sites: 20 Countries: France, Hungary, United Kingdom, United States�_
Patients: 78
ST Phase I/II EU
47 Multiple Myeloma
Sites: 7 Countries: Denmark, Spain, United Kingdom
Patients: 61
H-O Phase I EU
48 Lymphoma
Sites: 1 Countries: United Kingdom
Patients: 50
H-O Phase I EU
49 Tumour defined by Biomarker
Sites: 8 Countries: Canada, United Kingdom, United States
Patients: 36
ST Phase II GL
50 Myelofibrosis
Sites: 70 Countries: Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom
Patients: 150
H-O Phase III EU
51 Prostate
Sites: 4 Countries: United Kingdom, United States
Patients: 30
ST Phase I/II EU
52 Cholangiocarcinoma
Sites: 1 Countries: France
Patients: 12
ST Phase II EU
53 Lung
Sites: 1 Countries: France
Patients: 18
ST Phase II EU
54 Prostate
Sites: 7 Countries: France, Netherlands, United Kingdom
Patients: 30
ST Phase II EU
55 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 60
ST Phase I EU
56 Breast
Sites: 11 Countries: Czech, Hungary, Republic Russia
Patients: 46
ST Phase II EU
57 PHI-ST
Sites: 2 Countries: United States
Patients: 30
ST Phase I NA
58 Head & Neck
Sites: Up to 120 (60 non-us) Countries: Belgium, United Kingdom, United States
Patients: Minimum 100 and maximum 450*
ST Phase III EU
59 Ovarian
Sites: 3 Countries: United States
Patients: 24
ST Phase I NA
60 Renal
Sites: 3 Countries: United States
Patients: 30
ST Phase I NA
61 Melanoma
Sites: 3 Countries: United Kingdom
Patients: 36
ST Phase I EU
62 PHI-ST
Sites: 1 Countries: United States
Patients: 20
ST Phase I NA
63 Lymphoma
Sites: 6 Countries: France, Germany, United States
Patients: 30
H-O Phase I GL
64 PHI-HaemOnc
Sites: 1 Countries: United States
Patients: 34
H-O Phase I/II NA
65 Endometrial
Sites: 8 Countries: Canada, United States
Patients: 37
ST Phase II NA
66 PHI-HaemOnc
Sites: 1 Countries: United States
Patients: 25
H-O Phase I NA
67 PHI-ST
Sites: 3 Countries: United States
Patients: 40
ST Phase I NA
68 Lymphoma
Sites: 4 Countries: United States
Patients: 30
H-O Phase II NA
69 PHI-ST
Sites: 3 Countries: Austria, Denmark, Spain
Patients: 21
ST Phase I EU
70 PHI-ST
Sites: 4 Countries: United Kingdom, United States
Patients: 70
ST Phase I GL
71 PHI-HaemOnc
Sites: 4 Countries: United Kingdom, United States
Patients: 70
H-O Phase I GL
72 Myelodysplastic Syndrome
Sites: 2 Countries: United States
Patients: 50
H-O Phase I NA
73 Lymphoma
Sites: 2 Countries: United States
Patients: 40
H-O Phase I NA
74 Prostate
Sites: 1 Countries: United Kingdom
Patients: 50
ST Phase I EU
75 PHI-HaemOnc
Sites: 6 Countries: France, Germany, Norway, Sweden
Patients: 66
H-O Phase I EU
76 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 39
ST Phase I/IIa EU
77 PHI-ST
Sites: 5 Countries: United Kingdom
Patients: 48
ST Phase I/II EU
78 Melanoma
Sites: 5 Countries: United States
Patients: 63
ST Phase II NA
79 PHI-ST
Sites: 2 Countries: United States
Patients: 30
ST Phase I NA
80 PHI-HaemOnc
Sites: 2 Countries: United States
Patients: 30
H-O Phase I NA
81 PHI-ST
Sites: 11 Countries: Italy, Netherlands, Spain, United States
Patients: 130
ST Phase I/II GL
82 Lymphoma
Sites: 22 Countries: Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom
Patients: 30
H-O Phase II EU
83 Prostate
Sites: 2 Countries: United States
Patients: 20
ST Phase II NA
84 Pancreatic
Sites: 25 Countries: United States
Patients: 160
ST Phase I/II NA
85 AML
Sites: 139 Countries: United Kingdom
Patients: 1212
H-O Phase II/III EU
86 GBM
Sites: 1 Countries: United States
Patients: 24
ST Phase I NA
87 Renal
Sites: 30 Countries: United States
Patients: 300
ST Phase III NA
88 Multiple Myeloma
Sites: 8 Countries: United Kingdom, United States
Patients: 32
H-O Phase I GL
89 Lung
Sites: 20 Countries: United States
Patients: 103
ST Phase I/II NA
90 PHI-ST
Sites: 8 Countries: United States
Patients: 42
ST Phase I NA
91 Lymphoma
Sites: 12 Countries: United States
Patients: 23
H-O Phase II NA
92 PHI-ST
Sites: 1 Countries: United States
Patients: 30
ST Phase I NA
93 Lung
Sites: 15 Countries: United States
Patients: 36
ST Phase I/II NA
94 Prostate
Sites: 8 Countries: United States
Patients: 76
ST Phase I/II NA
95 Prostate
Sites: 13 Countries: Estonia, Latvia, United States
Patients: 30
ST Phase II GL
96 Prostate
Sites: 41 Countries: Russia, United States
Patients: 221
ST Phase II GL
97 Lung
Sites: 20 Countries: Europe, United States
Patients: 105
ST Phase II GL
98 Breast
Sites: 50 Countries: United States
Patients: 120
ST Phase II NA
99 PHI-ST
Sites: 3 Countries: United States
Patients: 22
ST Phase I NA
100 PHI-HaemOnc
Sites: 3 Countries: United States
Patients: 20
H-O Phase I NA
101 GBM
Sites: 28 Countries: Europe, Israel, United States
Patients: 236
ST Phase III GL
102 Lung
Sites: 50 Countries: United States
Patients: 115
ST Phase II NA
103 PHI-ST
Sites: 2 Countries: United Kingdom
Patients: 40
ST Phase I EU
104 Lung
Sites: 30 Countries: Canada, Germany, Hugary, Israel, Russia, United Kingdom, United States
Patients: 120
ST Phase II GL
105 Pancreatic
Sites: 42 Countries: United States
Patients: 109
ST Phase II NA
106 GBM
Sites: 31 Countries: Europe, Israel, United States
Patients: 283
ST Phase III GL
107 PHI-ST
Sites: 2 Countries: United States
Patients: 40
ST Phase I NA
108 PHI-HaemOnc
Sites: 4 Countries: United States
Patients: 25
H-O Phase I NA
109 Head & Neck
Sites: 4 Countries: United States
Patients: 25
ST Phase I NA
110 PHI-ST
Sites: 1 Countries: United States
Patients: 40
ST Phase I NA
111 Renal
Sites: 5 Countries: United States
Patients: 13
ST Phase II NA
112 Renal
Sites: 30 Countries: Canada, Europe, United States
Patients: 50
ST Phase II GL
113 Renal
Sites: 15 Countries: Canada, United States
Patients: 46
ST Phase I/II NA
114 Renal
Sites: 5 Countries: United States
Patients: 32
ST Phase I NA
115 PHI-ST
Sites: 3 Countries: United Kingdom
Patients: 12
ST Phase I EU
116 Bladder
Sites: 15 Countries: United States
Patients: 50
ST Phase II NA
117 Prostate
Sites: 5 Countries: United Kingdom, United States
Patients: 35
ST Phase II GL
118 Ovarian
Sites: 9 Countries: United States
Patients: 40
ST Phase BE NA
119 Ovarian
Sites: 20 Countries: Canada, France, Germany, Spain, United Kingdom
Patients: 172
ST Phase II GL
120 Breast
Sites: 1 Countries: United Kingdom
Patients: 20
ST Phase I EU
121 Lung
Sites: 1 Countries: United Kingdom
Patients: 12
ST Phase I/IIa EU
122 HCC
Sites: 1 Countries: United Kingdom
Patients: 39
ST Phase I/IIa EU
123 Lymphoma
Sites: 11 Countries: Europe, Korea, United States
Patients: 152
H-O Phase I/IIa GL
124 Myelofibrosis
Sites: 90 Countries: Australia, Canada, Europe, United States
Patients: 270
H-O Phase III GL
125 Intestine
Sites: 15 Countries: Canada, Germany, Netherlands, Spain, United Kingdom, United States
Patients: 150
ST Phase III GL
126 Ovarian
Sites: 3 Countries: United States
Patients: 27
ST Phase IIb NA
127 Head & Neck
Sites: 18 Countries: United States
Patients: 80
ST Phase II NA
128 Lung
Sites: 1 Countries: United Kingdom
Patients: 12
ST Phase I/IIa EU
129 PHI-ST
Sites: 3 Countries: United Kingdom
Patients: 100
ST Phase I EU
130 Myelodysplastic Syndrome
Sites: 16 Countries: France
Patients: 45
H-O Phase III EU
131 AML
Sites: 24 Countries: Belgium, France, Germany
Patients: 20
H-O Phase III EU
132 PHI-ST
Sites: 2 Countries: United States
Patients: 48
ST Phase I NA

No Results Found